Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Combination Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Reduced Dose ◽

Phase 2 Trial ◽

Vulnerable Patients ◽

Open Label Phase ◽

Dose Combination

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3652 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3652-TPS3652

Author(s):

Johanna C. Bendell ◽

Benjamin R. Tan ◽

James Andrew Reeves ◽

Henry Q. Xiong ◽

Rita Laeufle ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

International Journal of Clinical Oncology ◽

10.1007/s10147-020-01648-3 ◽

2020 ◽

Vol 25 (6) ◽

pp. 1123-1129

Author(s):

Yoshiharu Motoo ◽

Yasuto Tomita ◽

Hideto Fujita

Keyword(s):

Colorectal Cancer ◽

Peripheral Neuropathy ◽

Adjuvant Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Postoperative Adjuvant Chemotherapy ◽

Prophylactic Efficacy ◽

Phase 2 Trial ◽

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30272-4 ◽

2019 ◽

Vol 20 (8) ◽

pp. 1070-1082 ◽

Cited By ~ 43

Author(s):

Tanios S Bekaii-Saab ◽

Fang-Shu Ou ◽

Daniel H Ahn ◽

Patrick M Boland ◽

Kristen K Ciombor ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Dose Optimisation ◽

P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.100 ◽

2021 ◽

Vol 32 ◽

pp. S111

Author(s):

K. Raghav ◽

T. Yoshino ◽

H. Taniguchi ◽

S. Tejpar ◽

A. Vogel ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Previously Treated

PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.019 ◽

2021 ◽

Vol 32 ◽

pp. S199

Author(s):

S. Siena ◽

E. Elez ◽

M. Peeters ◽

T. André ◽

M. Van den Eynde ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30827-7 ◽

2020 ◽

Vol 21 (3) ◽

pp. 412-420 ◽

Cited By ~ 17

Author(s):

Per Pfeiffer ◽

Mette Yilmaz ◽

Sören Möller ◽

Daniela Zitnjak ◽

Merete Krogh ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00150-9 ◽

2016 ◽

Vol 17 (6) ◽

pp. 738-746 ◽

Cited By ~ 362

Author(s):

Andrea Sartore-Bianchi ◽

Livio Trusolino ◽

Cosimo Martino ◽

Katia Bencardino ◽

Sara Lonardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Proof Of Concept ◽

Wild Type ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Treatment Refractory ◽

Kras Codon

Faculty Opinions recommendation of Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726308902.793550903 ◽

2018 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Proof Of Concept ◽

Wild Type ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Treatment Refractory ◽

Kras Codon

An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2011.03.022 ◽

2011 ◽

Vol 10 (3) ◽

pp. 171-177 ◽

Cited By ~ 23

Author(s):

Allen L. Cohn ◽

Grace C. Shumaker ◽

Pankaj Khandelwal ◽

David A. Smith ◽

Marcus A. Neubauer ◽

...

Keyword(s):

Colorectal Cancer ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Second Line Therapy ◽

Phase 2 Trial ◽

Line Therapy

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Case Medical Research ◽

10.31525/ct1-nct04247256 ◽

2020 ◽

Author(s):

Keyword(s):

Colorectal Cancer ◽

Acquired Resistance ◽

Phase 2 ◽

Phase 2 Trial